Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Public comment periods — page 6

120 consultations carrying 1,332 signed submissions. Every submission has a declared interest, a secretariat response and a disposition.

Consultations

120 documents · page 6 of 6
  • CEI-CP-117ClosedEvidence synthesis11 May 2024 – 08 Jun 2024

    Consultation on the draft of this intervention review, which registers the question: Does the cardiovascular effect of a glucagon-like peptide-1 receptor agonist established in secondary prevention extend to a primary-prevention population?

    10 submissions
  • CEI-CP-085ClosedMethodological standard11 Apr 2024 – 06 Jun 2024

    Consultation on the draft of CEI-MS-03, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish. The draft states performance rather than prescribing a fixed…

    11 submissions2 not accepted
  • CEI-CP-094ClosedMethodological standard06 Apr 2024 – 05 Jun 2024

    Consultation on the draft of CEI-MS-15, which specifies the performance a determination must achieve for documentation and states what the resulting figure does not establish. The draft states performance rather than prescribing a fixed…

    12 submissions2 not accepted
  • CEI-CP-070ClosedCompound monograph05 May 2024 – 04 Jun 2024

    Consultation on the draft monograph for Petrelintide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…

    15 submissions
  • CEI-CP-052ClosedCompound monograph07 Feb 2024 – 07 Apr 2024

    Consultation on the draft monograph for GHRP-6, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for that…

    11 submissions2 not accepted
  • CEI-CP-020ClosedDocument series27 Jan 2024 – 27 Mar 2024

    Consultation on the format of the supplier dossier series: what a dossier contains, in what order, and what it declines to contain. The draft fixes a common structure so that two dossiers can be read against each other, and excludes any…

    10 submissions1 not accepted
  • CEI-CP-007ClosedCompound monograph07 Jan 2024 – 07 Mar 2024

    Consultation on the draft monograph for BPC-157. The draft records that the Institute identified no completed randomised controlled trial in humans reporting a clinical outcome, and grades the principal assessed outcome at very low…

    8 submissions1 not accepted
  • CEI-CP-053ClosedCompound monograph08 Feb 2024 – 07 Mar 2024

    Consultation on the draft monograph for Glutathione, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…

    14 submissions1 not accepted
  • CEI-CP-042ClosedCompound monograph23 Jan 2024 – 05 Mar 2024

    Consultation on the draft monograph for Cagrilintide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis for…

    16 submissions
  • CEI-CP-079ClosedCompound monograph25 Jan 2024 – 24 Feb 2024

    Consultation on the draft monograph for Teduglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis for…

    7 submissions
  • CEI-CP-084ClosedMethodological standard10 Jan 2024 – 24 Feb 2024

    Consultation on the draft of CEI-MS-02, which specifies the performance a determination must achieve for identity and states what the resulting figure does not establish. The draft states performance rather than prescribing a fixed…

    6 submissions
  • CEI-CP-103ClosedEvidence synthesis12 Jan 2024 – 23 Feb 2024

    Consultation on the draft of this intervention review, which registers the question: In adults with heart failure with preserved ejection fraction and obesity, what is the effect of an incretin receptor agonist on symptoms and on…

    4 submissions
  • CEI-CP-064ClosedCompound monograph12 Jan 2024 – 11 Feb 2024

    Consultation on the draft monograph for Maridebart cafraglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the…

    9 submissions1 not accepted
  • CEI-CP-015ClosedDocument series09 Oct 2023 – 08 Dec 2023

    Consultation on the scope and drafting conventions of the analytical and methodological standards series. The central question put was whether an Institute standard should prescribe a procedure or state the performance a determination must…

    9 submissions1 not accepted
  • CEI-CP-003ClosedMethodological standard11 Oct 2023 – 08 Nov 2023

    Consultation on the draft standard specifying the minimum data a certificate of analysis must carry before the Institute will treat it as interpretable. The draft classifies each field as critical or recommended and records that a…

    13 submissions1 not accepted
  • CEI-CP-024ClosedDocument series09 Aug 2023 – 23 Sep 2023

    Consultation on the set of indications the Institute assesses against and the anchor outcome defined for each. The draft fixes one anchor outcome per indication so that estimates carried in different documents are estimates of the same…

    15 submissions1 not accepted
  • CEI-CP-002ClosedEvaluation rubric06 Aug 2023 – 20 Sep 2023

    Consultation on the rubric by which the Institute assesses a supplier dossier. The rubric scores documentary and analytical practice; it does not score product quality, and the draft was released for comment principally because respondents…

    10 submissions2 not accepted
  • CEI-CP-004ClosedMethodological standard28 Apr 2023 – 28 May 2023

    Consultation on the draft of the Institute's first analytical standard, which specifies the performance a chromatographic purity determination must achieve and states, without qualification, that the resulting figure is a relative…

    5 submissions2 not accepted
  • CEI-CP-010ClosedGovernance document26 Jan 2023 – 23 Mar 2023

    Consultation on the policy governing the declaration and management of interests across the Institute, covering assessment committee members, external reviewers, contributors and respondents to consultations. The draft proceeds from the…

    12 submissions3 not accepted
  • CEI-CP-011ClosedGovernance document09 Jan 2023 – 10 Mar 2023

    Consultation on the policy governing what funding the Institute accepts, from whom, and on what published terms. The draft prohibits any funding arrangement that confers rights of review over an assessment before publication, and requires…

    10 submissions3 not accepted

page 6 of 6

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.